Postdoctoral Researcher in Translational Oncology

About the role

The Oncology Therapeutic Area of Eli Lilly and Company focuses on the discovery and development of small molecule and biologic therapeutics for patients with cancer. The Translational Sciences group within Lilly Oncology is responsible for bridging mechanistic discovery and clinical development, driving biomarker strategy, combination rationale, resistance biology and discovering novel indications across the oncology portfolio.

Responsibilities

• Investigate the role of cellular quality control pathways (unfolded protein response, heat shock response, autophagy) in response to compound activity using pharmacological and genetic perturbation approaches.
• Generate and characterize resistant cell line models using chronic dose escalation and genome-wide CRISPR-Cas9 knockout and activation screens to define genetic drivers of resistance and sensitization.
• Collaborate with Discovery Bioinformatics, conduct multi-omic profiling of sensitive and resistant models, integrating whole-genome sequencing, transcriptomics, and phospho-proteomics to identify predictive biomarkers of response.
• Analyze large-scale cell line and patient-derived xenograft datasets, linking baseline molecular features to compound activity for biomarkers and mechanism of action hypothesis generation.
• Evaluate immunomodulatory effects of compounds in tumor and immune cell compartments using multi-color flow cytometry, RNA-seq, and spatial transcriptomics in humanized mouse models and ex vivo co-cultures.
• Design and execute in vivo combination studies to establish preclinical rationale for clinical combination strategies.
• Prepare scientific reports, presentations, and publications detailing research outcomes.

Requirements

• PhD in cancer biology, cell biology, molecular biology, biochemistry, immunology, or a closely related discipline.
• Experience in one or more of the following areas: hands-on experience in oncology cell culture, in vitro pharmacology assays, and genetic modification techniques (transduction/transfection).
• Familiarity with targeted protein degradation platforms, including molecular glues, Ligand Directed Degraders (LDDs), or related modalities.
• Familiarity with multi-color full-spectrum flow cytometry and immunophenotyping.
• Experience with in vivo oncology pharmacology, including CDX/PDX tumor models and humanized mouse systems.
• Exposure to bispecific antibody or T cell engager research.
• Experience with multi-omics data types including proteomics, transcriptomics, and/or whole-genome sequencing.
• Prior experience in lymphoma, hematologic malignancies, or B cell biology; exceptional candidates from adjacent oncology disciplines will also be considered.
• Strong publication record demonstrating mechanistic rigor and translational relevance.
• Excellent communication and collaboration skills to work effectively in cross-functional teams.

Qualifications & Requirements

All requirements must be completed by September 2026. Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.